

GLOBAL & REGIONAL DAILY

HIGHLIGHTS

November 16, 2020

Global Markets

In spite of rising infection numbers around the world, risk-on sentiment prevailed early today on news that, after eight years of negotiations, China and another 14 countries in the Asia-Pacific region signed the world's largest regional free-trade agreement, the so-called Regional Comprehensive Economic Partnership (RCEP). Meanwhile, recent encouraging Covid-19 vaccine news continued to support risk sentiment, while positive data from China and Japan, also helped. China's industrial production expanded in October by a higher-than-expected 6.9%YoY, and in Japan, Q3 GDP grew by a record 21.4%QoQ annualized rate, supported by a strong rebound in domestic consumption. In FX markets, the USD remained under some pressure, ahead of October's retail sales and industrial production data from the US, both due on Tuesday.

Greece

The Deputy Minister for Social Insurance Panos Tsaklogou, stated in an interview that the bill for the partially funded insurance system will be submitted to Parliament in the H1-2021. The new system will be public, part of social security and mandatory for newcomers to the labour market from 1/1/2022 who are liable for supplementary insurance, while optional participation for insured persons under 35 years of age. In other news, according to press, new measures to ease the economic impact of the pandemic of €1.5 billion for Dec raise the total amount of the measures for Nov-Dec to €4.8 billion. Finally, this week the EC is expected to publish the new Enhanced Surveillance Report on Greece, which is this time linked to the disbursement of SMP/ANFA income of c. €645mn.

CESEE

SERBIA: The EUR/RSD lost a tiny bit of ground in the past week, ending in Friday's session at 117.52/57, but still remaining within the 9-month range of 117.50-117.65. The National Bank of Serbia (NBS) has sold EUR 1,735 mn from its reserves year-to-date so as to preserve the stability in the FX market amid heightened global uncertainty caused by the pandemic-induced crisis. Trading in bonds generated a turnover of EUR 54 mn in the secondary market, which is mostly owed to 12-year RSD denominated government securities. These bonds traded between 4.10%-4.25%. **CYPRUS:** According to the flash estimate, GDP on a seasonally adjusted basis rebounded by 9.4% QoQ in Q3, which translates into -4.4% YoY compared to -12.1% YoY in Q2 and +1.5% YoY in Q1. Thus, the GDP contraction in the first nine months has reached -5.1% YoY.

Contributing Authors

Paraskevi Petropoulou
Senior Economist
ppetropoulou@eurobank.gr

Anna Dimitriadou
Economic Analyst
andimitriadou@eurobank.gr

Ioannis Gkionis
Senior Economist
igkionis@eurobank.gr

Research Team



Dr. Tasos Anastasatos | Group Chief Economist
tanastasatos@eurobank.gr | + 30 214 40 59 706



Anna Dimitriadou
Economic Analyst
andimitriadou@eurobank.gr
+ 30 210 37 18 793



Ioannis Gkionis
Senior Economist
igkionis@eurobank.gr
+ 30 214 40 59 707



Dr. Stylianos Gogos
Economic Analyst
sgogos@eurobank.gr
+ 30 210 37 18 733



Maria Kasola
Economic Analyst
mkasola@eurobank.gr
+ 30 210 33 18 708



Olga Kosma
Research Economist
okosma@eurobank.gr
+ 30 210 37 18 728



Paraskevi Petropoulou
Senior Economist
ppetropoulou@eurobank.gr
+ 30 210 37 18 991



Dr. Theodoros Rapanos
Economic Analyst
v-trapanos@eurobank.gr
+ 30 214 40 59 711



Dr. Theodoros Stamatou
Senior Economist
tstamatou@eurobank.gr
+ 30 214 40 59 708



Elia Tsiampaou
Economic Analyst
etsiampaou@eurobank.gr
+ 30 214 40 59 712

Περισσότερες εκδόσεις μας διαθέσιμες στην ηλεκτρονική διεύθυνση που ακολουθεί: <https://www.eurobank.gr/en/group/economic-research>
Εγγραφείτε ηλεκτρονικά, σε: <https://www.eurobank.gr/el/omilos/oikonomikes-analuseis/forma-ekdilosis-endiaferontos>
Ακολουθήστε μας στο twitter: https://twitter.com/Eurobank_Group
Ακολουθήστε μας στο LinkedIn: <https://www.linkedin.com/company/eurobank>

DISCLAIMER

This report has been issued by Eurobank S.A. ("Eurobank") and may not be reproduced in any manner or provided to any other person. Each person that receives a copy by acceptance thereof represents and agrees that it will not distribute or provide it to any other person. This report is not an offer to buy or sell or a solicitation of an offer to buy or sell the securities mentioned herein. Eurobank and others associated with it may have positions in, and may effect transactions in securities of companies mentioned herein and may also perform or seek to perform investment banking services for those companies. The investments discussed in this report may be unsuitable for investors, depending on the specific investment objectives and financial position. The information contained herein is for informative purposes only and has been obtained from sources believed to be reliable but it has not been verified by Eurobank. The opinions expressed herein may not necessarily coincide with those of any member of Eurobank. No representation or warranty (express or implied) is made as to the accuracy, completeness, correctness, timeliness or fairness of the information or opinions herein, all of which are subject to change without notice. No responsibility or liability whatsoever or howsoever arising is accepted in relation to the contents hereof by Eurobank or any of its directors, officers or employees. Any articles, studies, comments etc. reflect solely the views of their author. Any unsigned notes are deemed to have been produced by the editorial team. Any articles, studies, comments etc. that are signed by members of the editorial team express the personal views of their author.

